Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ALXO
ALXO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALXO News
ALX Oncology Q4 2025 Earnings Call Highlights
Feb 27 2026
seekingalpha
ALX Oncology Q4 Earnings Miss Expectations, Shares Rise on Offering
Feb 27 2026
seekingalpha
ALX Oncology Reports Clinical Progress and Financial Update
Feb 27 2026
Newsfilter
ALX Oncology to Participate in Multiple Biotech Summits
Feb 19 2026
Newsfilter
ALX Oncology Shares Surge 10% After Major VC Purchase
Feb 04 2026
seekingalpha
ALX Oncology Announces Pricing of Underwritten Offering
Feb 02 2026
NASDAQ.COM
ALX Oncology Prices Underwritten Stock Offering
Jan 30 2026
seekingalpha
ALX Oncology Prices $150 Million Stock Offering to Fund Cancer Therapies
Jan 30 2026
Newsfilter
ALX Oncology's New Data Reinforces CD47 Biomarker Significance
Jan 30 2026
Newsfilter
ALX Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
Jan 08 2026
Globenewswire
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
ALXO Unveils Phase 2 Results of Evorpacept for Frontline Indolent Non-Hodgkin Lymphoma at ASH Conference
Dec 08 2025
NASDAQ.COM
ALX Oncology Achieves 92% Complete Response in Non-Hodgkin Lymphoma with Evorpacept Combination
Dec 07 2025
Globenewswire
ALX Oncology Reports 92% CR Rate in iNHL with Evorpacept Combination Therapy
Dec 07 2025
Newsfilter
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion
Nov 19 2025
Globenewswire
ALX Oncology to Showcase at Upcoming Investor Events
Nov 18 2025
Newsfilter
Show More News
